Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

A Phase III readout that boosted Marinus’ value on Tuesday is the first in a series of upcoming milestones that could lead to the company carving out a commercial niche in rare seizure disorders.

Trial results released late Monday showed that oral ganaxolone met the primary endpoint in the Phase III MARIGOLD trial, which evaluated the neurosteroid analog to treat CDKL5 deficiency disorder (CDD). The treatment reduced 28-day major motor seizure frequency by 32.2%  vs. 4.0% for placebo (p=0.002)...